{"title":"[2025年的放射性核素治疗：治疗转移性去势抵抗性前列腺癌的核医学选择]。","authors":"Luisa Willner, Robert Tauber, Matthias Eiber","doi":"10.1007/s00120-025-02526-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Radionuclide therapy continues to gain in importance thanks to promising clinical results. It is a suitable treatment option for many patients and is increasingly establishing itself as a key pillar in the treatment of metastatic castration-resistant prostate cancer (mCRPC).</p><p><strong>Objective: </strong>This article summarizes the current role of radionuclide therapies in the treatment of mCRPC and provides insights into recent developments.</p><p><strong>Methods: </strong>Presentation of key study results, current approval labels and ongoing clinical trials.</p><p><strong>Results: </strong>Significant prolongation of survival through treatment with lutetium-177-PSMA-617 and radium-223-dichloride has led to approval of both substances in late-stage mCRPC. Further study results on the effectiveness of lutetium-PSMA in earlier stages and on the use of the alpha emitter actinium-225 are expected.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"237-245"},"PeriodicalIF":0.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Radionuclide therapy in 2025: nuclear medicine options in the treatment of metastatic castration-resistant prostate cancer].\",\"authors\":\"Luisa Willner, Robert Tauber, Matthias Eiber\",\"doi\":\"10.1007/s00120-025-02526-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Radionuclide therapy continues to gain in importance thanks to promising clinical results. It is a suitable treatment option for many patients and is increasingly establishing itself as a key pillar in the treatment of metastatic castration-resistant prostate cancer (mCRPC).</p><p><strong>Objective: </strong>This article summarizes the current role of radionuclide therapies in the treatment of mCRPC and provides insights into recent developments.</p><p><strong>Methods: </strong>Presentation of key study results, current approval labels and ongoing clinical trials.</p><p><strong>Results: </strong>Significant prolongation of survival through treatment with lutetium-177-PSMA-617 and radium-223-dichloride has led to approval of both substances in late-stage mCRPC. Further study results on the effectiveness of lutetium-PSMA in earlier stages and on the use of the alpha emitter actinium-225 are expected.</p>\",\"PeriodicalId\":29782,\"journal\":{\"name\":\"Urologie\",\"volume\":\" \",\"pages\":\"237-245\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urologie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s00120-025-02526-4\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00120-025-02526-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/21 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
[Radionuclide therapy in 2025: nuclear medicine options in the treatment of metastatic castration-resistant prostate cancer].
Background: Radionuclide therapy continues to gain in importance thanks to promising clinical results. It is a suitable treatment option for many patients and is increasingly establishing itself as a key pillar in the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Objective: This article summarizes the current role of radionuclide therapies in the treatment of mCRPC and provides insights into recent developments.
Methods: Presentation of key study results, current approval labels and ongoing clinical trials.
Results: Significant prolongation of survival through treatment with lutetium-177-PSMA-617 and radium-223-dichloride has led to approval of both substances in late-stage mCRPC. Further study results on the effectiveness of lutetium-PSMA in earlier stages and on the use of the alpha emitter actinium-225 are expected.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
